Free Trial
NASDAQ:FLGT

Fulgent Genetics (FLGT) Stock Price, News & Analysis

Fulgent Genetics logo
$17.79 -0.63 (-3.42%)
(As of 04:32 PM ET)

About Fulgent Genetics Stock (NASDAQ:FLGT)

Key Stats

Today's Range
$17.65
$18.49
50-Day Range
$18.42
$22.91
52-Week Range
$17.65
$30.68
Volume
294,010 shs
Average Volume
181,666 shs
Market Capitalization
$544.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.50
Consensus Rating
Hold

Company Overview

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Fulgent Genetics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
84th Percentile Overall Score

FLGT MarketRank™: 

Fulgent Genetics scored higher than 84% of companies evaluated by MarketBeat, and ranked 181st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Fulgent Genetics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Fulgent Genetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Fulgent Genetics are expected to decrease in the coming year, from ($1.46) to ($1.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fulgent Genetics is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fulgent Genetics is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fulgent Genetics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Fulgent Genetics' valuation and earnings.
  • Percentage of Shares Shorted

    3.25% of the float of Fulgent Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulgent Genetics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Fulgent Genetics has recently decreased by 4.51%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fulgent Genetics does not currently pay a dividend.

  • Dividend Growth

    Fulgent Genetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.25% of the float of Fulgent Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulgent Genetics has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Fulgent Genetics has recently decreased by 4.51%, indicating that investor sentiment is improving.
  • News Sentiment

    Fulgent Genetics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Fulgent Genetics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 9 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,717.00 in company stock.

  • Percentage Held by Insiders

    31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fulgent Genetics' insider trading history.
Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Stock News Headlines

Piper Sandler Cuts Fulgent Genetics (NASDAQ:FLGT) Price Target to $22.00
Fulgent Genetics (NASDAQ:FLGT) Downgraded by StockNews.com to "Sell"
Elon Musk has put himself in their crosshairs
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
Fulgent Genetics price target lowered to $22 from $26 at Piper Sandler
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript
Fulgent Genetics Reports Q3 2024 Financial Performance
See More Headlines

FLGT Stock Analysis - Frequently Asked Questions

Fulgent Genetics' stock was trading at $28.91 at the beginning of 2024. Since then, FLGT stock has decreased by 37.3% and is now trading at $18.12.
View the best growth stocks for 2024 here
.

Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its quarterly earnings results on Friday, August, 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.45. The company's quarterly revenue was up 4.7% on a year-over-year basis.

The following companies are subsidiaries of Fulgent Genetics: Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC.

Fulgent Genetics (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics' top institutional shareholders include Charles Schwab Investment Management Inc. (0.81%), Principal Financial Group Inc. (0.32%), Empowered Funds LLC (0.30%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.15%). Insiders that own company stock include Hanlin Gao, Ming Hsieh, Jian Xie and Paul Kim.
View institutional ownership trends
.

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Meta Platforms (META), Advanced Micro Devices (AMD), PayPal (PYPL), Broadcom (AVGO) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/02/2024
Today
11/14/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:FLGT
Employees
1,184
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$28.50
High Stock Price Target
$35.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+58.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-167,820,000.00
Pretax Margin
-68.09%

Debt

Sales & Book Value

Annual Sales
$289.21 million
Cash Flow
$3.05 per share
Book Value
$37.10 per share

Miscellaneous

Free Float
20,873,000
Market Cap
$550.01 million
Optionable
Optionable
Beta
1.51

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:FLGT) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners